Psoriasis Pipeline Update: JNJ-2113, A Novel Oral IL-23 Receptor Antagonist Peptide, Shows Promise in a Phase 2b Study
Media formats available:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Recommended
Wilson Liao, MD
G. Michael Lewitt, MD
Annelies Isabelle Johanna Groen
Jennifer Cather, MD
Maria Bao-Loc-Trung, BS
George Jeha, MD
Deborah Hilton, MD
